It has long been recognized that effector cells of the immune system are required to ward off tumours and infectious agents. Likewise, it is well known that regulatory cells of the immune system rein in such responses, as well as guarding against immune dysregulation, such as that which occurs in allergy and autoimmunity. Even greater respect for this powerful homeostatic system has emerged over the past few years with the increasing appreciation that immune cells also affect important non-immune functions, including neurodegeneration, cardiovascular function and metabolism. This Focus issue of Nature Reviews Immunology, produced with support from sanofi-aventis, draws attention to an emerging frontier, immunometabolism -that is, the interplay between immunological and metabolic processes. On the one hand, it has emerged that certain supposedly non-immune pathologies result in mobilization of the innate and adaptive immune systems and, in the case of obesity, this promotes metabolic abnormalities, culminating in increased susceptibility to type 2 diabetes, cardiovascular diseases, cancer and neurodegeneration. On the other hand, it is now clear that the behaviours of lymphocytes and other leukocytes are controlled on many levels by internal metabolic properties. Dissection of the molecular underpinnings of the immunological-metabolic crosstalk has become a priority.
Obesity and chronic disease
The obesity epidemic continues unabated in Western countries, and is rising even more dramatically throughout the rest of the world, paradoxically even in the countries where poverty and malnutrition are most widespread. Coinciding with recent increases in obesity have been proportional increases in medical conditions with obvious metabolic connections, such as cardiovascular disease, type 2 diabetes, fatty liver disease and cirrhosis. Additional associations are being drawn between obesity and diseases that are less obviously linked to metabolic derangements, including asthma, Alzheimer's disease and several forms of cancer. Inflammation has been aetiologically linked to the pathogenesis of each of these conditions, and as obesity is causally linked to a systemic low-grade subacute inflammatory state, as well as inflammation in adipose tissue, obesity-induced inflammation may be a common pathogenic denominator.
Two articles in this Focus issue discuss the relationship between adipose tissue expansion and inflammation. The article by Ouchi et al. 1 focuses on adipokines, which are bioactive proteins that are produced by adipose tissues and have hormonal or cytokine actions locally and in other tissues. The article by Donath and Shoelson 2 discusses the immunological effects of expanding fat mass and inflammation in insulin resistance, and the effects of inflammation in pancreatic islets as these relate to the development and severity of type 2 diabetes.
Adipokines
Some adipokines, such as leptin and adiponectin, are produced exclusively (or at least predominantly) by adipose tissues, whereas other so-called adipokines are more typical pro-inflammatory or anti-inflammatory cytokines that are best known for their roles in innate and adaptive immune responses. The list of proinflammatory adipokines that are produced by fat
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Inflammation in type 2 diabetes
Attempts to target inflammation in type 2 diabetes have moved quickly for two main reasons. Foremost is the robustness of the clinical end point -that is, changes in measures of glycaemic control. Fasting blood glucose and glycated haemoglobin (HbA1c) levels are easily measured and highly accurate and reproducible. Fasting blood glucose changes within days to weeks of initiating a therapy, whereas HbA1c levels provide an 8-12 week integrated average blood glucose measure. It is therefore possible to test the efficacy of anti-inflammatory strategies within weeks for initial assessment and in months for highly predictive results. This is in contrast to assessments of drug efficacy and safety in other conditions such as cardiovascular disease, which require much larger trial sizes and durationand hence much greater cost -to assess true clinical outcomes. Trials of drugs to prevent Alzheimer's disease are even more challenging, as the common forms of the disease cannot be predicted before disease onset, and this makes trial size and duration, and costs, prohibitive. Clinical trials that assess effects on biomarkers that associate with cardiovascular disease or Alzheimer's disease can be smaller and of shorter duration, but their ability to predict clinical outcomes is often weak or unknown. As trials in type 2 diabetes can be conducted using reasonable numbers of subjects and at a reasonable cost, they may be used as a screen for potential anti-inflammatory treatments for other obesity-induced chronic diseases that are more difficult to study.
Completed and ongoing trials are testing this possibility. Three strategies discussed by Donath 5, 6 . Salsalate is a prodrug form of salicylate (an orally active, small-molecule anti-inflammatory drug) and has also been shown to lower blood glucose levels in patients with type 2 diabetes [7] [8] [9] . IL-1 antagonism and salsalate are both being tested further in larger clinical trials. Although small clinical trials using TnF blockade have not provided improvements in blood glucose levels in patients with type 2 diabetes, encouraging results in non-diabetic patients being treated with TnF blockers for other conditions suggest that this might be worth re-exploring.
Unique metabolic uses in immune cells
A completely different perspective on the immunological-metabolic interface is the extent to which, and the precise mechanisms by which, typical cell-intrinsic metabolic processes influence the performance of immune cells. In most cases, immune cells use and respond to nutrients similarly to other cells, so it is the exceptions to the rules that may be most interesting. The serine/threonine kinases AKT1-3, AmPK (AmPactivated protein kinase), mTOR (mammalian target of rapamycin) and LKB1 (also known as STK11) are generally thought of as cellular nutrient sensors that help to maintain energy homeostasis by relaying signals that determine how cells respond to high or low levels of intracellular carbohydrates or amino acids. Finlay and Cantrell 10 suggest that in addition to their more established roles in nutrient responses, AKT1-3, AmPK and LKB1 control a fate switch, from cytotoxic effector to memory CD8 + T cells. They argue that in CD8 + T cells the main role for the AKT proteins is to regulate repertoires of adhesion molecules and chemokine receptors and hence to control trafficking and migration, and that this is what determines the memory versus terminally differentiated effector decision in CD8 + T cells. A separate series of investigations looked at the effects of LKB1 in haematopoietic stem cells (HSCs) [11] [12] [13] . As noted above, in most cells LKB1 is a serine/threonine kinase that is upstream of AmPK (a master regulator of energy homeostasis) and mTOR complex 1 (mTORC1; a protein complex that controls protein synthesis and cell proliferation). These three reports showed that LKB1 regulates the function and dynamics of HSCs through pathways that are independent of AmPK and mTORC1. Deletion of Lkb1 in mice led to an initial expansion of HSCs and multipotent progenitors, but over time the cells were depleted and the mice became pancytopenic. moreover, an Lkb1 -/-bone marrow transplant was unable to reconstitute the haematopoietic system in irradiated mice, again suggesting that the survival of HSCs depends on LKB1. Together, these recent studies showed that under certain conditions, immune cells may use metabolic pathways to control fate and function in ways that are different from other cells. On the practical side, the finding that inflammation mediates many of the pathological consequences of obesity raises the hope of exploiting the existing armamentarium of antiinflammatory drugs, or future ones, to treat patients with obesity-associated metabolic and cardiovascular disorders (and even perhaps some cancers and neurodegenerative diseases). underscoring this potential, the type 2 diabetes drug metformin has shown promise in cancer prevention 14 , and is being tested in trials for its ability to prevent various cancers. And even more to the point, a daily dose of aspirin (an anti-inflammatory salicylate) correlates with reduced death from several different cancers 15 .
in addition to their more established roles in nutrient responses, AKT1-3, AMPK and LKB1 control a fate switch, from cytotoxic effector to memory CD8 + T cells.
